Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H1 2020, provides an overview of the Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline landscape.
Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.
Report Highlights Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 4 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.
Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Our reports have been used by over 10K customers, including:
415 pages •
By Global Industry Analysts
• Apr 2021
- The global market for X-ray Detectors is projected to reach US$3.5 billion by 2025 supported by the key role played by imaging and diagnosis in managing the global burden of chronic diseases. Under-diagnosis of chronic diseases is a key reason for rising disability-adjusted life years (DALY), emergency healthcare...
Blood Purification Equipment Market by Product Type(Portable and Stationary), Indication (Sepsis, Renal Diseases, and Others) and End User (Hospitals and Clinics, Dialysis Centers and Others): Global Opportunity Analysis and Industry Forecast, 2020–2027
Blood purification allows removal of toxic or pathogenic substances...
120 pages •
By Infiniti Research Limited
• Feb 2021
Global Polycystic Ovary Syndrome (PCOS) Drugs Market 2021-2025 The analyst has been monitoring the polycystic ovary syndrome (PCOS) drugs market and it is poised to grow by $ 711.14 mn during 2021-2025 progressing at a CAGR of 5% during the forecast period. Our report on polycystic ovary syndrome (PCOS) drugs market provides...
Wearable Injectors Market Size, Share & Trends Analysis Report By Type (On-body, Off-body), By Technology (Spring-based, Motor-driven), By Application (Oncology, Autoimmune Diseases), By End Use, And Segment Forecasts, 2021 - 2028 Wearable Injectors Market Growth & Trends The global wearable...
KEY FINDINGS The Asia Pacific cartilage repair market is estimated to project a CAGR of 16.84% during the forecast period, 2021-2028. The increasing need for sophisticated medical facilities, the growing prevalence of lifestyle diseases resulting in bone & joint ailments, and the rising R&D activities, are propelling the...
Generic injectables are bio-equivalents of their branded counterparts which are not protected by drug patents. They are as safe and effective as the innovator drugs since they have similar active ingredient, dosage, strength, quality, form, etc. Although the manufacturing of generic injectables is complex, their R&D...
The global smoothies market reached a value of around US$ 14 Billion in 2020. A smoothie refers to a thick beverage which is prepared by blending an assortment of fruits, vegetables and other ingredients including milk, seeds, yogurt, ice-cubes, sweeteners, and nutritional and herbal supplements. It is high in nutrients...
513 pages •
By Global Industry Analysts
• Apr 2021
- The global market for Contrast Media is projected to reach US$5.3 billion by 2025, driven by the growing number of imaging procedures such as X-Rays, MRI, CT, and Ultrasound supported by the prevalence of chronic diseases among the growing global population and the ensuing diagnostic burden and demand for imaging...
192 pages •
By Global Industry Analysts
• Apr 2021
- Global Chronic Kidney Disease (CKD) Drugs Market to Reach $15.7 Billion by 2027
- Amid the COVID-19 crisis, the global market for Chronic Kidney Disease (CKD) Drugs estimated at US$13.7 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 1.9% over...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.